Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39Carcinoma, Intraductal, Noninfiltrating 6Breast Carcinoma In Situ 5Inflammatory Breast Neoplasms 4Central Nervous System Neoplasms 3Liver Neoplasms 2Gliosarcoma 2Glioma 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Brain Neoplasms 2Astrocytoma 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Sarcoma 1Recurrence 1Pheochromocytoma 1Ovarian Neoplasms 1Osteosarcoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1

Interventions

trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cystadenocarcinoma, Serous × Tamoxifen × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡